Key result
Newer rotary LVAS improve survival and reduce adverse events versus first-generation pulsatile devices.
This review outlines the technological evolution of implantable LVAS for advanced heart failure, emphasizing the transition to rotary blood pumps to mitigate complications associated with earlier pulsatile devices.
Answers are grounded in this paper and cite their sources.
May inform rotary LVAS selection in advanced HF; leaves open need for randomized confirmation.
The first clinical application of the first-generation pulsatile implantable left ventricular assist system (LVAS) was in the mid 1980 s as a bridge to transplantation and contributed to an advancement of this field from a clinical experiment to an established therapeutic option for treating advanced heart failure patients. However, there have been technological limitations that have surfaced as longer-term experience has been gained. These include a high incidence of thromboembolic complications, infection, mechanical failures associated with moving parts, and the large size of both implantable pump and percutaneous cable. In order to overcome the limitations of the first-generation pulsatile LVAS, a smaller rotary blood pump LVAS emerged as a possible alternative in the 1990 s and these new generation LVAS are in various stages of development and clinical application. This article reviews the history and current status of the implantable LVAS.
No takes yet. Share an insight, caveat, or question.
Chisato Nojiri (2009) conducted a review in Advanced heart failure. Implantable Left Ventricular Assist Systems (LVAS) was evaluated. Newer generation rotary pump left ventricular assist systems demonstrate better survival outcomes, mechanical reliability, and decreased adverse event rates compared to first-generation pulsatile devices.
Synapse has enriched 10 related papers. Consider them for comparative context: